UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): January 4, 2017
 
KaloBios Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-35798
 
77-0557236
(State or other Jurisdiction of
Incorporation)
 
(Commission File No.)
 
(IRS Employer Identification No.)
 
 
1000 Marina Boulevard, Suite 250
Brisbane, CA  94005-1878
 (Address of principal executive offices, including zip code)
 
(650) 243-3100
(Registrant’s telephone number, including area code)
 
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 

 

 
Item 7.01
Regulation FD Disclosure.

On January 5, 2017, KaloBios Pharmaceuticals, Inc., (the “Company”) reported that on January 4, 2017, the U.S. Food and Drug Administration (FDA) released the minutes from a recent meeting with the Company. In the minutes, FDA provided the Company positive guidance regarding its development plans for benznidazole for the treatment of Chagas disease, a neglected tropical disease.

On January 5, 2017, the Company issued a press release, a copy of which is being furnished as Exhibit 99.1 to this Report on Form 8-K and the contents of which are incorporated herein by reference.

Item 9.01.
Financial Statements and Exhibits.

(d)
Exhibits

Exhibit No.
 
Description
99.1
 
Press Release dated January 5, 2017
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
           
 
KaloBios Pharmaceuticals, Inc.
 
 
   
 
By:
/s/ Cameron Durrant
 
 
Name: Cameron Durrant
Title:   Chairman of the Board and Chief Executive Officer
 
Dated: January 5, 2017
 

 
Exhibit Index
 
Exhibit No.
 
Description
99.1
 
Press Release dated January 5, 2017